Brief: Initiator Pharma Signs Option Agreement For Late-Stage Drug Candidate
April 5 (Reuters) - Initiator Pharma A/S INIT.ST :
* INITIATOR PHARMA SIGNS OPTION AGREEMENT FOR LATE-STAGE
DRUG
CANDIDATE
* SIGNED AN EXCLUSIVE OPTION AGREEMENT FOR A PHASE 2/3 READY
DRUG
ASSET FOR AN UNDISCLOSED PAIN INDICATION
* EXCLUSIVE OPTION AGREEMENT CONTAINS NO UPFRONT OR INITIAL
MILESTONE PAYMENTS
Source text for Eikon: ID:nMFN7J4gtq
Further company coverage: INIT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Initiator Pharma A/S
See all newsBrief: Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
Brief: Initiator Pharma To Fully Prioritize Pudafensine
Brief: Initiator Pharma Reports Q4 Net Revenue Of DKK 0.00
Brief: Initiator Pharma Q4 Operating Loss Widens To DKK 7 Mln
Brief: Initiator Pharma Granted European Patent For Pudafensine in FSD